SCIB1 Plus Nivolumab/Ipilimumab Generates ORR of 85% in Adva

SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma.

Related Keywords

Nottingham , United Kingdom , Lindy Durrant , University Of Nottingham , Academic Department Of Clinical Oncology , Academic Department , Clinical Oncology , Scib1 , Nivolumab , Ipilimumab , Melanoma ,